Mitsubishi Chemical Group Corporation (TSE: 4188), Japan's largest diversified chemicals group, reported FY2026/3 consolidated results under IFRS that combined a sharp reset of the legacy materials portfolio with a record performance in industrial gases. Continuing-operations revenue declined 6.2% year-on-year to ¥3,703.9 billion, reflecting a wave of divestitures (J-Film, certain triacetate fibres, a high-purity terephthalic acid subsidiary and the coke business), softer downstream demand and weaker MMA monomer prices, partly offset by FX tailwinds and newly consolidated industrial gas acquisitions. Core operating profit edged down only 1.7% to ¥225.0 billion, while reported operating profit plunged 78.8% to ¥30.1 billion on much higher non-recurring charges. Pre-tax profit collapsed 99.3% to a near-breakeven ¥0.7 billion.
Net profit attributable to owners of the parent from continuing operations fell 73.7% to ¥11.8 billion (basic EPS of ¥8.63 versus ¥31.64 prior year). Including discontinued operations, however, group total profit reached ¥78.4 billion, supported by ¥94.8 billion of discontinued-operations earnings that included a ¥128.6 billion gain on the Tanabe Pharma divestiture (net of ¥36.7 billion in related taxes). Comprehensive income surged to ¥251.9 billion, helped by ¥164.3 billion of positive FX translation adjustments on yen weakness.
Industrial Gases is the standout — core operating profit hits a record ¥200.7 billion
By segment, Industrial Gases delivered a standout year, with revenue up ¥51.4 billion to ¥1,352.5 billion and core operating profit up ¥14.6 billion to a record ¥200.7 billion, driven by pricing management, cost reductions, FX, and contributions from acquired businesses in Europe and Oceania. Specialty Materials revenue slipped ¥11.7 billion to ¥1,059.6 billion, but core operating profit rose ¥8.4 billion to ¥32.3 billion as semiconductor-related engineering plastics and carbon-fibre composite parts grew and prior-year Gelest impairment effects unwound, despite a Soarnol-related impairment in the UK.
MMA & Derivatives was the weakest pocket: revenue fell ¥65.7 billion to ¥351.9 billion and the segment swung to a ¥1.5 billion core operating loss (down ¥37.2 billion YoY) on MMA monomer price weakness and softer coatings, adhesives and additives demand. Basic Materials & Polymers revenue dropped ¥195.9 billion to ¥790.7 billion, but the segment's core operating loss narrowed by ¥10.4 billion to ¥4.2 billion on wider polyolefin spreads, inventory valuation gains in carbon, and structural-reform benefits, despite ethylene oxide / ethylene glycol facility impairments.
¥80 billion legacy clean-up: coke withdrawal and "Next Stage Support Program"
Non-recurring items weighed heavily on operating profit. The group booked ¥61.4 billion of impairment losses, ¥59.2 billion of restructuring provisions, and ¥53.1 billion of special retirement payments. Roughly ¥80 billion of these charges related to the withdrawal decision on the coke and carbon materials businesses (across restructuring provisions, impairments, special retirement and inventory write-downs). Mitsubishi Chemical Corporation's "Next Stage Support Program" contributed an additional ¥31.9 billion in special retirement payments plus ¥0.7 billion of related losses.
Two-deal industrial-gas footprint expansion
M&A reshaped the gases franchise. Effective July 1, 2025, the group acquired Coregas Pty Ltd and three affiliates (carved out from Wesfarmers) for ¥71.5 billion cash, booking ¥27.5 billion in goodwill alongside ¥37.3 billion in property, plant and equipment and ¥13.5 billion in intangibles (mainly customer relationships). On March 3, 2026, European subsidiary Oximesa acquired Esteve Teijin Healthcare (renamed Nippon Sanso Homecare España) for ¥22.4 billion cash, with provisional goodwill of ¥10.8 billion.
Balance sheet: Tanabe sale proceeds repair leverage
Total assets stood at ¥5,876.6 billion (down ¥18.0 billion) as Tanabe Pharma sale proceeds and yen depreciation offset the asset disposal. Interest-bearing debt including lease liabilities fell ¥156.6 billion to ¥2,021.9 billion; equity rose ¥130.1 billion to ¥2,414.7 billion. The parent-owner equity ratio improved 0.5pp to 30.0%, and the net debt-to-equity ratio improved 0.23 to 0.83x. Operating cash flow came in at ¥436.3 billion (down ¥116.5 billion), investing cash flow turned positive at ¥124.5 billion on ¥517.5 billion of subsidiary-sale proceeds, and financing cash flow was negative ¥375.2 billion on debt repayments, dividends, and ¥50.0 billion of buybacks. Cash and equivalents closed at ¥527.1 billion.
The annual dividend for FY2026/3 was held flat at ¥32.00 per share (¥16 interim + ¥16 year-end), totalling ¥43.5 billion at a 370.8% consolidated payout ratio. Management guides the same ¥32.00 dividend for FY2027/3.
FY27 guidance: a sharp rebound expected
For FY2027/3, the group forecasts revenue of ¥3,800.0 billion (+2.6%), core operating profit of ¥305.0 billion (+35.6%), operating profit of ¥300.0 billion (+897.4%), pre-tax profit of ¥270.0 billion, net profit of ¥200.0 billion (+155.0%), and profit attributable to owners of the parent of ¥127.0 billion (+973.6%), implying basic EPS of ¥93.48. Drivers are higher Specialty Materials sales and cost reductions plus an expected bottoming and recovery in MMA monomer markets. The forecast assumes FX of ¥150/USD and naphtha at ¥63,000/KL. Management flagged geopolitical risks around the Strait of Hormuz as not embedded in the guidance — a sustained Middle East disruption through September could trim core operating profit by roughly ¥18 billion.
| Metric | FY2026/3 | FY2025/3 | YoY |
|---|---|---|---|
| Revenue (¥ billion) | 3,703.9 | 3,948.2 | −6.2% |
| Core operating profit (¥ billion) | 225.0 | 228.9 | −1.7% |
| Operating profit (¥ billion) | 30.1 | 142.0 | −78.8% |
| Net profit attrib. to owners (¥ billion) | 11.8 | 44.9 | −73.7% |
| Basic EPS (¥) | 8.63 | 31.64 | −72.7% |
| Parent-owner equity ratio | 30.0% | 29.5% | +0.5pp |
| Net debt/equity | 0.83x | 1.06x | −0.23 |
| Annual dividend (¥) | 32.00 | 32.00 | — |
JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.